Cell and Gene Therapy for Personalised Medicine (CGT4PM2027) – European Partnership on Personalised Medicine

Di cosa tratta questo bando?

The call funds research projects that develop and validate innovative cell and gene therapies for personalised medicine in human health. It is a joint transnational call of the European Partnership for Personalised Medicine.

Cosa finanzia questo bando?

Scope

This joint transnational call of the European Partnership for Personalised Medicine (EP PerMed) funds research projects in human health on cell and gene therapies for personalised medicine approaches.

Focus of proposals

Proposals must focus on the development and validation of an innovative and novel cell or gene therapy for personalised medicine. At least one of the following approaches must be employed: somatic cell therapeutics, gene therapeutics, combined cell and gene therapeutics, or novel biological products.

Further information

The full scope is set out in the call text published on the EP PerMed website. The call runs in two stages, with pre-proposals followed by full proposals. Applicants should contact their regional or national representative to enquire about eligibility with their funding organisations before applying, and adherence to regional and national funding regulations in the Guidelines for Applicants is mandatory.

Quando scade il bando?

Pre-proposals are due on 20 January 2027, 14:00 CET. Full proposals are due on 25 May 2027, 14:00 CEST.